Trials / Completed
CompletedNCT00084279
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)
Safety and Tolerability of Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV) in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a (2a or 2b) Plus RBV
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin | interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily |
Timeline
- Start date
- 2004-04-01
- Completion
- 2006-04-01
- First posted
- 2004-06-11
- Last updated
- 2009-07-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00084279. Inclusion in this directory is not an endorsement.